MNKD

MANNKIND CORP

Nasdaq · CIK 899460

Last close3.8
Daily change-0.15 (-3.80%)
10 Years gain+20.63%
Dividends TTM0
Dividend yield0.00%

Fundamental Analysis

MNKD · STANDARD

SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231

Screener
Fundamental
62.9
Momentum
0.0
Acceleration
0.0
Confidence
79.0
Annual Revenue16
Quarterly Revenue51
Annual CFO15
Balance SheetAvailable
RankingEligible

Score Breakdown

Growth18.7 / 25
Quality17.6 / 25
Capital Efficiency16.9 / 20
Balance Sheet7.2 / 15
Shareholder Economics1.6 / 10
Forward Indicators0.9 / 5

Signals

Share count reductionDiluted share count declined 3.6479%.

Warnings

Receivables anomaly · MEDIUMAccounts receivable growth is materially above revenue growth.
Inventory anomaly · MEDIUMInventory growth is materially above revenue growth.
Gross margin compression · MEDIUMGross margin compressed by 2.9519 percentage points.
Operating margin compression · MEDIUMOperating margin compressed by 17.6292 percentage points.
Possible growth trap · HIGHRevenue growth is high, but quality indicators are deteriorating.

Key Metrics

Revenue Growth TTM24.77%OK
Revenue CAGR 3Y51.8%OK
Gross Margin91.34%OK
Operating Margin6.19%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Y28.65%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-3.65%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL

Financial History

PeriodRevenueGross ProfitOperating IncomeCFOFCFGross MarginOp MarginFCF MarginROICShares
2025 FY Dec 31, 2025$348.97M$322.17M$38.80M$18.26M$13.69M92.32%11.12%3.92%n/a314.11M
2025 FY Dec 31, 2024$285.50M$268.08M$72.59M$42.51M$32.82M93.9%25.42%11.49%n/a283.84M
2025 FY Dec 31, 2023$198.96M$178.10M$8.68M$34.09M-$8.35M89.51%4.36%-4.2%n/a267.01M
2024 FY Dec 31, 2022$99.77M$83.77M-$64.11M-$80.68M-$88.27M83.96%-64.26%-88.47%n/a257.09M
2023 FY Dec 31, 2021$75.44M$58.61M-$47.02M-$61.71M-$73.18M77.69%-62.33%-97%n/a249.24M

Formula Trace

MetricValueFormulaStatusSource
Revenue TTM$358.20Msum latest 4 fiscal quarters RevenueOK0001193125-26-335054, 0001193125-25-265813
Revenue Growth TTM24.77%Revenue_TTM / Revenue_TTM_1Y_ago - 1OK0001193125-26-335054, 0001193125-25-265813
Revenue CAGR 3Y51.8%(Revenue_current / Revenue_3Y_ago)^(1/3) - 1OK0001193125-26-073516
Revenue CAGR 5Y39.89%(Revenue_current / Revenue_5Y_ago)^(1/5) - 1OK0001193125-26-073516
Gross Profit CAGR 3Y56.68%(GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1OK0001193125-26-073516
Operating Income Growth-67.57%OperatingIncome_current / OperatingIncome_prior_year - 1OK0001193125-26-335054, 0001193125-25-265813
FCF Growthn/aFCF_current / FCF_prior_year - 1INSUFFICIENT_HISTORYderived
Revenue Growth Accelerationn/a0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3)INSUFFICIENT_HISTORYderived
Gross Profit Accelerationn/a0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3)INSUFFICIENT_HISTORYderived
Operating Income Accelerationn/a0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3)INSUFFICIENT_HISTORYderived
FCF Accelerationn/a0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3)INSUFFICIENT_HISTORYderived
Gross Margin91.34%Gross Profit / RevenueOK0001193125-26-335054, 0001193125-25-265813
Operating Margin6.19%Operating Income / RevenueOK0001193125-26-335054, 0001193125-25-265813
Net Debt / CFOn/aNet Debt / CFONOT_MEANINGFUL0001193125-26-335054
Current Ratio1.72xCurrent Assets / Current LiabilitiesOKderived
Cash / Debt0.35x(Cash + Short-term Investments) / Total DebtOK0001193125-26-335054
Revenue per Diluted Share$1.16Revenue / Diluted SharesOK0001193125-26-335054, 0001193125-25-265813
SBC / FCFn/aSBC / FCFNOT_MEANINGFULderived